PDX Pharmaceuticals Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$250K
- Investors
-
6
PDX Pharmaceuticals General Information
Description
Developer of functionalized nanomaterials designed to improve health care using nanotechnology. The company's tool is a hybrid of polymer coating and inorganic nanoparticle core which focuses on novel nanomaterials from the hybrid of organic and inorganic materials, enabling researchers and patients with cures for the treatment of breast, prostate, and pancreatic cancers, fibrosis, and hyperphosphatemia.
Contact Information
Website
www.pdxpharm.comCorporate Office
- Center for Health & Healing Building 1, 3303 South Bond Avenue
- CH13B, 13th Floor
- Portland, OR 97239
- United States
Corporate Office
- Center for Health & Healing Building 1, 3303 South Bond Avenue
- CH13B, 13th Floor
- Portland, OR 97239
- United States
PDX Pharmaceuticals Timeline
PDX Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Grant | 23-Sep-2024 | $250K | Completed | Clinical Trials - Phase 1 | ||
| 12. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 11. Grant | 01-Jan-2023 | Completed | Clinical Trials - Phase 1 | |||
| 10. Grant | 23-Sep-2021 | Completed | Clinical Trials - Phase 1 | |||
| 9. Grant | 01-Sep-2021 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC (Series A) | 27-Jan-2021 | Completed | Clinical Trials - Phase 1 | |||
| 7. Grant | 01-Jan-2018 | Completed | Clinical Trials - Phase 1 | |||
| 6. Accelerator/Incubator | 25-Oct-2017 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 16-May-2017 | $2.06M | Completed | Clinical Trials - Phase 1 | ||
| 4. Grant | 01-Jan-2017 | $550K | Completed | Clinical Trials - Phase 1 |
PDX Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A.1 | ||||||||
| Series A |
PDX Pharmaceuticals Comparisons
Industry
Financing
Details
PDX Pharmaceuticals Competitors (31)
One of PDX Pharmaceuticals’s 31 competitors is Ability Pharma, a Private Equity-Backed company based in Cerdanyola, Spain.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| Cristal Therapeutics | Venture Capital-Backed | Maastricht, Netherlands | ||||
| Dauntless Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| AB Science | Formerly Accelerator/Incubator backed | Paris, France | ||||
| Etana Biotech | Venture Capital-Backed | East Jakarta, Indonesia |
PDX Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PDX Pharmaceuticals Patents
PDX Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021307416-A1 | Immunogenic constructs, compositions, and methods for inducing immune response | Inactive | 13-Jul-2020 | ||
| CA-3182756-A1 | Immunogenic constructs, compositions, and methods for inducing immune response | Pending | 13-Jul-2020 | ||
| EP-4178627-A1 | Immunogenic constructs, compositions, and methods for inducing immune response | Pending | 13-Jul-2020 | ||
| US-20220111039-A1 | Immunogenic constructs, compositions, and methods for inducing immune response | Inactive | 13-Jul-2020 | ||
| US-20230233668-A1 | Immunogenic constructs, compositions, and methods for inducing immune response | Inactive | 13-Jul-2020 | A61K39/12 |
PDX Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PDX Pharmaceuticals Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Wayne D. Kuni and Joan E. Kuni Foundation | Impact Investing | Minority | ||
| National Institutes of Health | Government | |||
| National Cancer Institute | Government | |||
| National Center For Advancing Translational Sciences | Government | |||
| U.S. Department of Health and Human Services | Government |
PDX Pharmaceuticals FAQs
-
When was PDX Pharmaceuticals founded?
PDX Pharmaceuticals was founded in 2010.
-
Where is PDX Pharmaceuticals headquartered?
PDX Pharmaceuticals is headquartered in Portland, OR.
-
What is the size of PDX Pharmaceuticals?
PDX Pharmaceuticals has 8 total employees.
-
What industry is PDX Pharmaceuticals in?
PDX Pharmaceuticals’s primary industry is Drug Discovery.
-
Is PDX Pharmaceuticals a private or public company?
PDX Pharmaceuticals is a Private company.
-
What is PDX Pharmaceuticals’s current revenue?
The current revenue for PDX Pharmaceuticals is .
-
How much funding has PDX Pharmaceuticals raised over time?
PDX Pharmaceuticals has raised $3.55M.
-
Who are PDX Pharmaceuticals’s investors?
Wayne D. Kuni and Joan E. Kuni Foundation, National Institutes of Health, National Cancer Institute, National Center For Advancing Translational Sciences, and U.S. Department of Health and Human Services are 5 of 6 investors who have invested in PDX Pharmaceuticals.
-
Who are PDX Pharmaceuticals’s competitors?
Ability Pharma, Cristal Therapeutics, Dauntless Pharmaceuticals, AB Science, and Etana Biotech are some of the 31 competitors of PDX Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
